Peter Zhang: Is Canada Ready for the Gene Therapy Era?
Peter Zhang, Director, Business Acceleration at Odaia, shared a post on LinkedIn:
”My latest in The Hill Times on gene therapies, and whether the Canadian healthcare system is ready for these innovative medicines.
When I was a board member with Hemophilia Ontario (now known as Bleeding Disorders Ontario), I was excited to hear about its patient impact firsthand.
This year, a Canadian with severe hemophilia B received the first gene therapy approved in Canada. But a single dose can cost more than $4 million, and payers need to approach patient access in an equitable and sustainable manner.
Canada also needs to consider its strategy for future innovations in gene therapy and it’s encouraging that there is ongoing work to leverage this technology to introduce therapies for patients living with Huntington’s disease, spinal muscular atrophy, and inherited retinal diseases.”
Stay updated with Hemostasis Today.
-
Jul 9, 2026, 09:35Pradeebha Muthukumar: Do You Know the Signs of Anemia?
-
Jul 9, 2026, 09:24Maryam Majid: Machine Learning for Anemia Risk Prediction
-
Jul 9, 2026, 08:46Jordan Agay: Folate Deficiency in Patients Receiving PARP Inhibitors
-
Jul 9, 2026, 08:29Laura Katz: Is Human Lactoferrin Better Than Bovine Lactoferrin?
-
Jul 9, 2026, 08:17Anziya Sabeer: AI-Driven Non-Invasive Anemia Detection
-
Jul 9, 2026, 07:37Variable Mechanisms of ADAMTS13 Inhibition by Autoantibodies in iTTP – JTH
-
Jul 9, 2026, 07:31DHR-Sponsored Training Programme at ICMR-CRMCH Week 2 – Day 4 – ICMR-NIRBID
-
Jul 9, 2026, 06:03Barbara Adams Krolak: ISTH Launches Global Women’s Health Hub
-
Jul 9, 2026, 05:49Abdul Mannan: A Low Platelet Count is not Always a Bone Marrow Problem